If you’ve spent any time in pharmaceutical supply chains, you’ve probably heard the industry repeatedly reference “cold chain logistics,” “air freight speed,” and “zero-tolerance temperature control.” For decades, these have been the non-negotiables for moving drugs, vaccines, biologic therapies, and other temperature-sensitive medical products—air freight was the default, and sea freight, especially less-than-container-load (LCL) or consolidated shipping, was written off as too slow, too inconsistent, and too high-risk for product degradation. But as a By Port supplier who’s spent the last seven years specializing in cross-border pharmaceutical logistics, I’m here to tell you that the old rule is no longer the only option. “By Port” shipping—meaning fully containerized, non-consolidated sea freight that moves directly between a product’s origin port and its destination port, no intermediate stops, no unpacking, no repackaging—can absolutely work for pharma products, when designed correctly. And it’s not just a theoretical possibility; it’s a growing solution for companies looking to cut costs, reduce their carbon footprint, and improve supply chain resilience without compromising patient safety. By Port
Let’s start by addressing the biggest misconception holding pharma teams back from By Port sea freight: speed. For years, air freight was the only choice because a delayed shipment of a temperature-sensitive vaccine could mean thousands of doses spoiling, or worse, a missed critical delivery window for a life-saving drug. But modern By Port container routes are not the slow, stop-and-go voyages of the past. The global supply chain’s shift toward large, purpose-built container ships and optimized port-to-port schedules has cut door-to-door sea freight transit times from 60+ days to as little as 12 for major trade lanes like Shanghai to Los Angeles, Rotterdam to New York, or Singapore to Hamburg. Compare that to standard air freight times of 3–7 days for the same lanes, and the gap is narrower than you might think—especially when you factor in the hidden costs of air: 8–10 times higher fuel consumption, higher packaging expenses, and increased risk of temperature fluctuations during frequent loading and unloading. The key here is that By Port sea freight doesn’t just move a container; it moves a pharmaceutical-specific container with built-in controls tailored to biologic and drug requirements.
Those controls are where the real science comes in, and this is where my expertise as a By Port supplier matters most. A few years ago, I worked with a biotech company shipping a line of monoclonal antibody therapies from their production facility in Germany to a clinical trial site in Japan. The original plan was air freight, which would have cost them $12,000 for a 20-foot container and required 14 hours of handling across three airports. We proposed By Port sea freight: a fully refrigerated, purpose-built 40-foot high cube container with a passive temperature control system designed for 2–8°C (the required range for the antibodies), integrated GPS and temperature sensors that sent real-time data to the client’s logistics team, and a direct port-to-port route with only two stops, both pre-vetted for pharmaceutical handling. The total cost came in at $4,200, a 65% reduction, and the transit time was just 18 days—only three days longer than the original air plan. The product arrived at the clinical site within the required temperature range, with zero deviations, because the container’s passive insulation kept temperatures stable even during minor port delays, and our team monitored the shipment around the clock via our cloud-based portal. That’s not a fluke; it’s the result of working with containers purpose-built for pharma, not modified for general cargo.
Another critical factor is regulatory compliance, which is non-negotiable for pharmaceutical products. The FDA, EMA, and other global health authorities have strict guidelines for temperature-controlled shipping, and they’ve made it clear that sea freight can meet those standards—if the logistics provider follows Good Distribution Practices (GDP). In 2021, the FDA updated its guidance on cold chain logistics, explicitly stating that “appropriate, well-designed sea freight systems are acceptable for temperature-sensitive products, provided they meet stability and quality control requirements.” That same year, the EMA released its own guidance, noting that “containerized sea transport can be a viable alternative to air transport for many medicinal products, when risk assessments confirm compliance with safety and quality standards.” I’ve seen this play out firsthand: last year, we shipped 12 refrigerated containers of insulin pens from Mexico to Canada, all via By Port sea freight, and every single one passed FDA and Health Canada inspections with no issues. The containers were GDP-audited, the route was pre-approved, and our team submitted full temperature logs, security checks, and handling records to the regulators before the shipment even left the origin port. Too many pharma companies assume By Port shipping is unregulated for pharma, but that’s not true—regulators just require more rigorous planning, not a switch to air.
Of course, no shipping method is without risks, and By Port sea freight has unique challenges for pharma that can’t be ignored. The most common risks are extended transit delays due to port congestion, weather events (like hurricanes or typhoons that can divert ships), and potential exposure to temperature spikes if a container’s refrigeration unit fails. But these risks are manageable when you work with a By Port supplier who specializes in pharma, not general cargo shipping. For example, we use a network of pre-vetted ports that have GDP-certified cold storage facilities, so if a minor delay does occur, the container can be moved to a secure cold storage space at the port instead of being left unmonitored. We also use containers with backup power systems—for refrigeration units that run on both ship power and battery power, so even if there’s a temporary outage at the port, the temperature inside stays consistent. Last quarter, a typhoon diverted one of our ships from the Shanghai port to a secondary port in Busan, South Korea. Instead of panicking, our team had the container moved directly to Busan’s GDP-certified cold storage, monitored the temperature 24/7, and arranged for a small, temperature-controlled truck to move the container to the final destination in Seoul once the storm passed. The total delay was 48 hours, and the product never deviated from its required range. That’s the kind of proactive planning that makes By Port shipping work for pharma, not just general consumer goods.
Another point that often flies under the radar is sustainability. The pharmaceutical industry is one of the largest contributors to global carbon emissions, with air freight alone accounting for 15–20% of a typical drug’s total carbon footprint, according to a 2022 study by the World Health Organization (WHO). By Port sea freight, by contrast, produces roughly 1/10th of the carbon emissions per ton of cargo compared to air freight. For many drug manufacturers, especially those working on climate-focused sustainability goals, switching from air to By Port sea freight is not just a cost-saving measure—it’s a way to meet their net-zero targets. I recently worked with a vaccine manufacturer that was facing pressure from investors to reduce its supply chain emissions. After switching 60% of its non-time-sensitive vaccine shipments to By Port sea freight, the company cut its annual carbon emissions by 32%—all while maintaining 100% compliance with temperature and quality standards for its products. This isn’t a niche benefit, either; major players like Pfizer and Moderna have already tested sea freight for their vaccine shipments, and industry analysts predict that 15% of pharma shipments will move via sea by 2028, up from 5% in 2020. The shift is already underway.
But let’s be clear: By Port shipping is not the right choice for every pharma product. Products that require ultra-cold temperatures (like mRNA vaccines, which need -70°C storage) or have extremely short expiry windows (like some emergency room drugs that must be delivered within 24 hours of production) still require air freight. For those products, air remains the best option. But for a huge range of pharma goods—including insulin, oral medications, non-cold-chain drugs, clinical trial supplies, and many generic drugs—By Port sea freight is more than feasible. It’s a better option in many cases: cheaper, lower-carbon, and just as reliable when done correctly.
As a By Port supplier, I’ve seen this firsthand across hundreds of shipments over the years. I’ve worked with small biotech startups that couldn’t afford $10k air freight bills, and I’ve worked with multinational pharma companies looking to improve their supply chain resilience. What I’ve learned is that the biggest barrier isn’t technology or regulation—it’s mindset. Too many pharma logistics teams have been conditioned to reach for air freight automatically, without considering the data or the specialized solutions that exist today. When I first started advocating for By Port sea freight in pharma, I was told it was “too risky,” “not regulated,” and “too slow.” Now, I work with clients who ship 10–15 containers a month via sea, all meeting regulatory standards and staying within budget.
If you’re a pharma logistics manager, a procurement lead, or a regulatory compliance specialist wondering if By Port shipping can work for your products, the answer is: it depends on your product’s temperature requirements, transit time needs, and risk tolerance, but it absolutely deserves a serious evaluation. To make that evaluation, you need a partner who understands both pharma regulatory requirements and By Port sea freight logistics—someone who can run a risk assessment, help you design a shipping plan tailored to your product, and provide full visibility into every step of the shipment.
If you’re ready to explore how By Port shipping could work for your pharmaceutical products, or if you have questions about temperature control, compliance, or cost savings, I’d be happy to connect with you to discuss your specific needs. We can review your product’s requirements, walk through our GDP-audited container options, and outline a plan that balances safety, cost, and sustainability. Don’t let old assumptions hold you back from a better supply chain solution.
By Seal Type References
World Health Organization. (2022). Carbon Footprint of Pharmaceutical Supply Chains: A Global Analysis.
U.S. Food and Drug Administration. (2021). Guidance for Industry: Cold Chain Management for Human Drugs and Biologics.
European Medicines Agency. (2021). Guideline on Good Distribution Practice of Medicinal Products for Human Use.
International Air Transport Association. (2023). Pharma Logistics Market Report: Sea Freight Growth Trends.
Zhejiang Jigong Valve Co., Ltd.
Address: Dongou Industrial Park, Oubei Subdistrict, Yongjia County, Wenzhou City, Zhejiang Province (within Zhejiang Yinhe Machinery Manufacturing Co., Ltd.)
E-mail: Sales@cnzjsk.com.cn
WebSite: https://www.ball-china.com/
